Virco N.V.
Records under this name other than patents Virco N.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,563,236 | Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance Term ended Term ended Oct 9, 2021 · From the USPTO record | Term ended | Term ended Oct 9, 2021 | From the USPTO record |
| US 7,235,387 | Method for mutation detection in HIV-1 using pol sequencing Term ended Term ended May 16, 2021 · From the USPTO record | Term ended | Term ended May 16, 2021 | From the USPTO record |
| US 6,800,463 | Method for mutation detection in HIV-1 using pol sequencing Term ended Term ended Aug 18, 2020 · From the USPTO record | Term ended | Term ended Aug 18, 2020 | From the USPTO record |
| US 7,494,768 | Mutational profiles in HIV-1 protease and reverse transcriptase correlated with phenotypic drug resistance Term ended Term ended May 30, 2020 · From the USPTO record | Term ended | Term ended May 30, 2020 | From the USPTO record |
| US 6,221,578 | Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains Formerly held Term ended Term ended Jul 24, 2018 · From the USPTO record | Term ended | Term ended Jul 24, 2018 | From the USPTO record |
| US 7,058,616 | Method and system for predicting resistance of a disease to a therapeutic agent using a neural network Formerly held Lapsed on the fee record Ended Jun 6, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jun 6, 2018 | From the USPTO record |
| US 8,574,831 | Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance Lapsed on the fee record Ended Nov 5, 2017 · From the USPTO record | Lapsed on the fee record | Ended Nov 5, 2017 | From the USPTO record |
| US 7,292,944 | Establishment of biological cut-off values for predicting resistance to therapy Formerly held Lapsed on the fee record Ended Nov 6, 2015 · From the USPTO record | Lapsed on the fee record | Ended Nov 6, 2015 | From the USPTO record |
| US 7,206,699 | Methods for measuring therapy resistance Formerly held Lapsed on the fee record Ended Apr 17, 2015 · From the USPTO record | Lapsed on the fee record | Ended Apr 17, 2015 | From the USPTO record |
| US 6,528,251 | Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains Formerly held Lapsed on the fee record Ended Mar 4, 2015 · From the USPTO record | Lapsed on the fee record | Ended Mar 4, 2015 | From the USPTO record |